The in vitro antibacterial activity of meropenem and up to nine other antimicrobials was compared in studies at 26 North American centers from 1989 to 1992 with use of standardized and controlled procedures for determining minimal inhibitory concentrations (MICs) against 12,483 recent clinical isolates and additional drug-resistant strains. Overall, carbapenems were the most active drugs. The antibacterial activity of meropenem was consistent against random isolates in all centers; however, inclusion of large proportions of multidrug-resistant gram-negative aerobes by some centers did increase MICs of meropenem and the comparators. Meropenem was 4 -64 times more active than imipenem against gram-negatives, including Enterobacteriaceae organisms, Pseudomonas aeruginosa, Burkholderia cepacia, Neisseria meningiditis, and Haemophilus influenzae. Imipenem was up to 2-4 times more active than meropenem against some gram-positive cocci, including Enterococcus faecalis. Carbapenems were similarly active against anaerobes, and resistant strains were rarely encountered. Meropenem, unlike imipenem or ceftazidime, was bactericidal for all strains of Enterobacteriaceae, P. aeruginosa, and gram-positive cocci tested at .-__ 8 times the MIC. A lack of antibiotic cross-resistance was frequently observed between comparator-resistant strains and meropenem. These data suggest the potential utility of meropenem as a monotherapeutic agent against a broad range of pathogens.
. The raw data from individual centers were examined and then pooled for this meta-analysis, and trends associated with these merged data were evaluated to examine the degree of antimicrobial cross-resistance among the clinical isolates and also to determine if there were geographic differences in susceptibility patterns.
Methods
Investigational sites. In vitro studies were conducted at 26 geographically separate medical centers and hospitals located in 17 states in the United States (24 centers) and 2 Canadian provinces, as shown in the acknowledgment at the end of the text.
Antimicrobials. The 10 antimicrobials used in these studies, which comprised 2 carbapenems and 6 other classes of compounds (including an extended-spectrum penicillin, cephalosporins, aminoglycosides, and 3 agents selected for their antianaerobic activity), were obtained from their manufacturers. The study drugs were meropenem (Zeneca Pharmaceuticals Bacterial isolates. The majority of strains were unique, randomly selected clinical isolates. To further challenge this new carbapenem, additional isolates resistant to at least one of the following classes of antimicrobials were also chosen: /3-lactam compounds, aminoglycosides, ciprofloxacin, clindamycin, or metronidazole. A total of 12,483 isolates were evaluated.
The following groups of bacteria were represented: Enterobacteriaceae (4, 836) , aerobic nonfermentative gram-negative bacilli (NFB) (1, 894) , another group of miscellaneous fastidious aerobic and capnophilic gram-negative rods (1, 474) , aerobic gram-positive bacteria (3, 181) , and anaerobes (1, 098) . A complete distribution of organisms tested is summarized in table 1. Since these in vitro studies were conducted at 26 different centers, not all strains of each species were tested against each antimicrobial; hence, the number of strains tested against each antimicrobial varies.
Susceptibility testing. MICs were determined with use of National Committee for Clinical Laboratory Standards (NCCLS)-recommended methodology and media for agar dilution or broth microdilution techniques, which in almost all cases included cation-adjusted Mueller-Hinton broth or Mueller-Hinton agar [22] [23] [24] [25] . In most studies involving fastidious microorganisms, such as Haemophilus influenzae and Neisseria species, supplemented GC medium base (Difco Laboratories, Detroit, MI) or Haemophilus Test Medium (Prepared Media Laboratories, Portland, OR) was employed. Three centers used other media for testing these isolates, including chocolate agar plus nicotinamide adenine dinucleotide and Kellogg's supplement [20] , Iso-Sensitest agar plus Levanthal's supplement [13] , and medium supplemented with IsoVitaleX [11] .
All investigators included NCCLS-recommended ATCC or other quality-control strains with each MIC study to ensure consistent results between laboratories. MBCs were determined by the NCCLS-recommended broth microdilution technique [26] . The MBC was defined as the lowest concentration of antibiotic causing at least a three-log (99.9%) reduction in the inoculum after overnight incubation. MBC:MIC ratios were calculated with use of a subgroup containing 95 Enterobacteriaceae strains, 33 P. aeruginosa strains, and 9 strains of grampositive cocci.
MIC resistance breakpoints. The NCCLS-recommended antimicrobial MIC resistance breakpoints (ciprofloxacin,. --4 ii,g/mL; clindamycin, _-8 p,g/mL; imipenem, tobramycin, and gentamicin, _--16 p,g/mL; ceftazidime and metronidazole, _.32 p,g/mL; cefotaxime and cefoxitin, ._-64 p,g/mL; and piperacillin, ._-128 ,u,g/mL) were used for commercially available antimicrobials. A provisional MIC resistance point of __16 pg/mL was used for meropenem.
Results
For the purpose of analyses, all raw data concerning all random isolates and the additional resistant isolates were combined.
Enterobacteriaceae. As shown in table 2, meropenem emerged as the most active agent against 4,836 Enterobacteriaceae strains tested, with an overall MIC 50 of <0.063 ,ug/mL for the entire group. The corresponding MIC 90 for the group was 0.125 p,g/mL. These MICs were lower than those for any of the comparator drugs against this family of common pathogens. The meropenem MIC 90 values for individual species ranged from 0.03 p,g/mL for Escherichia coli and Citrobacter diversus to 0.5 pg/mL for Serratia marcescens. For imipenem the overall MIC50 and MIC90 were 0.25 p,g/mL and 2 ,ug/mL, respectively.
The imipenem MIC 90 values for individual species ranged from 0.125 p,g/mL for E. coli to 4 p,g/mL for Proteus mirabilis and Proteus vulgaris. For the other comparators, the overall MIC50 values ranged from <0.25 kig/mL to 4 //g/mL, and the overall MIC90 values were 4 p,g/mL to > 128 p,g/mL. For individual species, the MIC 90 values ranged from 0.25 11 ghnl, to > 128 p,g/mL. Table 3 demonstrates that meropenem was 8-to 32-fold more active than imipenem against Citrobacter, Proteus, and Providencia species and up to 512-fold more active than cephalosporin or aminoglycoside comparators against several selected species. Figure 1 shows that essentially all strains that were resistant to comparative antibiotics, excluding imipenem, were susceptible to meropenem. Ninety-three percent to 98% of these resistant strains were susceptible and an additional 4% to 2% were moderately susceptible to meropenem (.4. ig/mL and 8 pg/mL). Furthermore, 35% and 42% of strains resistant to imipenem were susceptible or moderately susceptible to meropenem.
As depicted in table 4, only eight (0.2%) of the 4,836 Enterobacteriaceae strains tested were resistant to meropenem (MIC, _-16 p,g/mL). These resistant isolates included strains of C. diversus (1) , Citrobacter freundii (1) , Enterobacter cloacae (1) , Morganella morganii (2), and S. marcescens (3). Furthermore, most meropenem-resistant strains were also resistant to comparator antibiotics, including imipenem.
Meropenem, imipenem, and ceftazidime demonstrated potent bactericidal activity against a subgroup of 95 strains of Enterobacteriaceae when this parameter was evaluated. Of added interest was the finding that the MBC:MIC ratios for meropenem were ,4 for 97% of the following strains of Enterobacteriaceae tested: C. freundii (2) , Enterobacter aerogenes (3), E. cloacae (13) , E. coli (11) , P. mirabilis (21) , and S. marcescens (45); the ratios were 8 for the remaining 3% of strains. The MBC:MIC ratios for imipenem were ---..8 for 97% of strains. Ceftazidime MBC:MIC ratios were ...4 for 99% of strains tested but were _.-16 for 1% of strains. The MBC:MIC ratios for imipenem or for ceftazidime were _-16 in tests of 9% and 5%, respectively, of P. mirabilis strains.
Aerobic NFB. As depicted in tables 2 and 3, meropenem was the most active agent against 1,894 strains of NFB, with an overall MICR, of 1 ,ag/mL and a corresponding MIC 90 of 16 ii,g/mL. The overall MIC R, and MIC90 for imipenem were 2 ,ug/mL and 32 p,g/mL, respectively. As shown in table 3, the meropenem MIC90 values for the individual species of NFB listed ranged from 4 p,g/mL for P. aeruginosa to 8 pg/mL for NOTE. Cfox = cefoxitin; Cm = clindamycin; Ctax = cefotaxime; Czid = ceftazidime; Gm = gentamicin; Imi imipenem; Mem = meropenem; Mtr = metronidazole; ND = not determined; Pip = piperacillin; Tm = tobramycin.
B. cepacia.
As shown in the table for the same two species, the imipenem MIC90 values ranged from 16 pg/mL for P. aeruginosa to 32 tg/mL for B. cepacia.
For the other comparators, as shown in table 2, the overall MIC90 values ranged from 32 pg/mL to >128 pg/mL for all species tested. When all individual species of NFB are considered, the MIC90 values of the comparators ranged from 1 ug/mL to > 128 pg/mL. Stenotrophomonas maltophilia and Flavobacterium meningosepticum were resistant to all antibiotics tested.
As depicted in table 3, when individual isolates of aerobic NFB were evaluated, meropenem emerged as the most active of all agents against 1,182 strains of P. aeruginosa, with an MIC50 of 0.5 pg/mL and an MIC 90 of 4 iig/mL. Furthermore, meropenem inhibited 71% and 81% of strains at 1 tg/mL and 2 .tg/mL concentrations, respectively. The overall MIC 50 and MIC90 values of imipenem for P. aeruginosa were 2 pg/mL and 16 pg/mL, respectively, as shown in table 3. However, imipenem inhibited 44% and 68% of strains at 1 ,u,g/mL and 2 pg/mL, respectively. The MIC 90 values of the other comparators ranged from 32 pg/mL to > 128 pg/mL.
As depicted in table 5, the frequencies of resistance of P. aeruginosa strains to comparators ranged from a low of 12.5% for imipenem to a high of 39.8% for cefotaxime, compared with 4.2% for meropenem at the proposed resistance breakpoint (. -16 ug/mL). Among the 147 imipenem-resistant P. aeruginosa isolates, 41% were inhibited by a4 pg/mL and 71% were inhibited by s 8 pg/mL of meropenem (figure 2). Table 4 provides additional data on P. aeruginosa strains resistant to meropenem; the majority of these strains were also resistant to at least one of the comparator antibiotics.
Potent bactericidal activity was demonstrated by meropenem, imipenem, and ceftazidime against 33 strains of P. aeruginosa. The MBC:MIC ratios of meropenem and ceftazidime were for all strains tested. The corresponding MBC:MIC ratios of imipenem were 8 for 97% of all strains tested.
As shown in table 3, the meropenem MIC 50 and MIC90 values for B. cepacia were 2 pg/mL and 8 ii,g/mL, respectively. Meropenem inhibited 40%, 63%, and 70% of strains at concentrations of 1 pg/mL, 2 pg/mL, and 4 pg/mL, respectively. Comparative MIC50 and MIC90 values of imipenem were 8 itglmL and 32 ,u,g/mL, respectively, but imipenem inhibited 25%, 28%, and 37% of strains at concentrations of 1 pg/mL, 2 pg/mL, and 4 pg/mL, respectively.
For the other comparators, the MIC 50 values for B. cepacia ranged from 4 .tg/mL to 64 pg/mL, and the MIC 90 values ranged from 32 pg/mL to 128 .tg/mL. Table 5 demonstrates that the rate of resistance of B. cepacia strains to meropenem (8.9%) was low in comparison with the 42.3% of strains resistant to imipenem. The majority of B. cepacia strains that were resistant to comparator antibiotics were susceptible or moderately susceptible to meropenem (figure 3); of particular interest was the fact that 56% and 87%, respectively, of B. cepacia strains resistant to imipenem were susceptible or moderately susceptible to meropenem.
Other miscellaneous gram-negative rods. As depicted in table 2, meropenem was the most active agent against 1,474 individual strains of miscellaneous aerobic and capnophilic gram-negative rods, including Moraxella, Pasteurella, and Yersinia species, with an overall MIC 50 of 0.031 pg/mL and a comparable MIC 90 of 0.125 ,ug/mL for all species in the group. The MIC90 values of meropenem for individual species in the group ranged from 0.016 ,ag/mL to 1 ii,g/mL. In contrast, the overall MIC50 and overall MIC90 of imipenem were 0.25 90 , 0.008 tg/mL), and Haemophilus ducreyi (MIC90, 0.125 pg/mL) than was imipenem, of which the MICK, values were 0.25, 0.125, 0.125, and 0.5 tg/mL, respectively, against these isolates. /3-Lactamase-producing strains were included. Meropenem (MIC90, 0.031 p,g/mL) was more active than ceftazidime (MIC90, 0.063 ps/mL) against N. gonorrhoeae. The MIC90 of cefotaxime (0.031 ,ug/mL) demonstrated that it had somewhat greater activity than meropenem (MIC 90 , 0.125 pg/mL) against H. influenzae.
Aerobic gram positive bacteria. The susceptibility of 3,178 aerobic gram-positive bacteria to meropenem varied greatly across species lines. The overall MIC50 of meropenem was 0.031 pg/mL and the corresponding MIC 90 was 8 //g/mL. As shown in table 3, the MIC 90 values of meropenem against individual species ranged from 0.125 sg/mL for Streptococcus pneumoniae to 8 ,ug/mL for Enterococcus faecalis. The overall MIC90 of imipenem for aerobic gram-positive bacteria was 2 .tg/mL, and for individual species, the MIC 90 ranged from 0.06 pg/mL for S. pneumoniae to 2 ug/mL for E. faecalis.
For the other comparators, the overall MIC 90 values ranged from__.-16 tg/mL to 64 p,g/mL, and the MIC 90 values for the (8 , ug/mL) was somewhat higher than that of imipenem (2 pg/mL), it was lower than those of the two aminoglycosides (32 µg/mL and -64 µg/mL) and much lower than those of the two cephalosporins tested (> 128 pg/mL). Seventy-four percent of E. faecalis strains were inhibited by a 4-µg/mL concentration of meropenem. All drugs' MIC 90 values were elevated against strains of Enterococcus faecium and
Corynebacterium jeikeium.
As shown in figure 4 , many of the gram-positive cocci resistant to all of the comparator antibiotics other than imipenem were susceptible or moderately susceptible to meropenem (4 //g/mL and 8 µg/mL, respectively). Furthermore, of all of the imipenem-resistant strains, 5% and 14% were susceptible or moderately susceptible, respectively, to meropenem.
Potent bactericidal activity of meropenem, imipenem, and ceftazidime was demonstrated against nine strains of grampositive organisms tested. The MBC:MIC ratios for meropenem were -__4 for all tested strains of S. aureus (4) , S. epidermidis (3) , and E. faecalis (2) . MBC:MIC ratios for imipenem against all S. aureus and E. faecalis isolates and for ceftazidime against all S. aureus isolates were .--_4. The MBC:MIC ratio for imipenem and ceftazidime against the same strains of S. epidermidis was -8.
Anaerobic strains. Carbapenems were the most active agents tested against 1,072 anaerobic strains. The overall MIC 50 of meropenem, as shown in table 2, was 0.125 ,ug/mL, and the overall MIC90 was 1 pg/mL. The MIC 90 values for the individual species ranged from <0.016 µg/mL to 4 µg/mL. The overall MiC50 and MIC90 values of imipenem were 0.125 µg/mL and 2 µg/mL, respectively. For individual species, the MIC90 values of imipenem ranged from 0.031 ii,g/mL to 4 µg/mL.
When two commonly isolated Bacteroides species were tested, meropenem MIC 90 values of 0.5 pg/mL and 1.0 µg/mL were reported for Bacteroides fragilis and B. thetaiotaomicron, whereas the imipenem MIC90 values for both species were 1 pg/mL. For the other comparators, the overall MIC 90 values were 4 ,ag/mL to 64 ,cog/mL. The MIC 90 values reached >128 iug/mL for some individual species. As shown in table 2, the overall MIC90 values for the two carbapenems against anaerobes ranged from 2-to 64-fold lower than those of other comparators, and resistance of anaerobes to carbapenems was rare: 0.2% were resistant to imipenem and 0.4% to meropenem.
As depicted in figure 5 , almost all (-94%) of the anaerobic species resistant to cefoxitin, metronidazole, or clindamycin were susceptible or moderately susceptible to meropenem. Both carbapenems tested, meropenem and imipenem, inhibited almost all clinical isolates of B. fragilis, B. thetaiotaomicron, and Clostridium difficile strains that were resistant to cefoxitin or clindamycin. The maximum MIC90 values of meropenem were 0.25 ktg/mL against two commonly isolated gram-positive anaerobic species: Peptostreptococcus and Propionibacterium.
Geographical variations in susceptibility test data. The overall MIC90 of meropenem against S. marcescens was 0.5 pg/mL, however, one center in Delaware reported a meropenem MIC90 of 8 pg/mL and an imipenem MIC 90 of 4 pg/ mL for 38 strains (data on file, Zeneca Pharmaceuticals). In a center in Texas [16] , where seven strains of S. marcescens were tested, enhanced proportions (14.3%-42.9%) of strains were resistant to all /3-lactam antimicrobial agents and 28.6% were resistant to gentamicin; these strains were more resistant to several antimicrobials than were random isolates.
The overall MIC 90 of meropenem against Acinetobacter calcoaceticus var. anitratus was 2 itg/mL; however, one center in Pennsylvania reported a meropenem MIC 90 of 32 µg/mL and an imipenem MIC 90 of 16 //g/mL for 28 strains (data on file, Zeneca Pharmaceuticals). For up to 21% of A. calcoaceticus var. anitratus strains from this center, the MICs of carbapenems were 16 pg/mL or greater; in comparison, <2% in the 10 other centers where this organism was tested were associated with such MICs. Enhanced proportions of these 28 strains were also resistant to ceftazidime (78.6%), ciprofloxacin (71.4%), and tobramycin (28.6%); thus, they were more resistant to several antimicrobials than were random isolates.
The overall MIC 90 of meropenem against P. aeruginosa was 4 iig/mL, however, one center in Texas [16] reported that for 20% of the 25 strains tested, MICs were at least 16 ,ug/mL. In this center the incidences of resistance to the comparator drugs among the selected strains tested were as follows: imipenem, 32%; ceftazidime, 36%; cefotaxime, 72%; piperacillin, 36%; ciprofloxacin, 32%; and gentamicin, 72% (data on file, Zeneca Pharmaceuticals). Strains of P. aeruginosa tested in this center were more resistant to several antimicrobials than were random isolates.
The overall MIC 90 of meropenem against B. cepacia was 8 p,g/mL. Meropenem MICs of ...16 ,ug/mL were observed for >7% of strains in only two (in New York and Massachusetts) of the seven centers where this organism was tested. In contrast, for at least 32.3% of strains in all 7 centers the MICs of imipenem were _---16 ktg/mL, and in 4 of 5 centers the MICs of ciprofloxacin were n4 ,ug/mL for at least 25% of strains.
Discussion and Conclusions
A high degree of antimicrobial activity of meropenem against the total of > 12,000 randomly selected and purposely chosen drug-resistant isolates was confirmed at all 26 North American centers. The wide battery of aerobic, capnophilic, and anaerobic pathogens was purposely selected to evaluate the spectrum of the compound as well as its potential use in managing the types of pathogens commonly occurring in monomicrobial infections as well as infections containing complex polymicrobial flora, such as those anticipated at intraabdominal sites.
Unlike comparator 0-lactam drugs, meropenem demonstrated bactericidal activity against all organisms tested at MIC multiples (MBC/MIC) of -_8 and at clinically relevant drug concentrations. Furthermore, most gram-negative enteric rods resistant to comparator antibiotics were characteristically susceptible to meropenem. The few strains resistant to meropenem were frequently also resistant to multiple comparator antibiotics. In this trial, meropenem emerged as the most active drug against both randomly selected and purposely chosen multidrug-resistant strains of Enterobacteriaceae, with an overall MIC90 of only 0.125 ktg/mL, compared with a range of n2 pg/mL to -128 btg/mL for all of the other drugs tested. These data are supported by results from other countries, including Germany [1] , United Kingdom [2] , Japan [4] , and France [9] .
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Czid ( Figure 3 . In vitro antimicrobial activity of meropenem against Burkholderia cepacia isolates selected for resistance to comparator antibiotics. White and black areas indicate, respectively, the proposed breakpoints for susceptibility (4 ,ug/mL) and moderate susceptibility (8 ktg/mL) to meropenem. Refer to figure 1 legend for MIC resistance breakpoints and drug abbreviations.
It is interesting that meropenem was 2-to 4-fold more active than imipenem the only other carbapenem evaluated and the second most active drug against randomly selected or specifically chosen drug-resistant P. aeruginosa and B. cepacia strains, thereby confirming data already published for P. aeruginosa [27] . The few strains associated with elevated MICs of meropenem were frequently also resistant to the comparator drugs, but many strains resistant to the comparator drugs were inhibited by meropenem at concentrations of u 8 pg/mL.
In this study, the MIC50 of meropenem (0.5 ,ag/mL) may represent more accurately the antibacterial activity against random P. aeruginosa isolates than the MIC90 (4 ktg/mL) because of the intentional inclusion of some selected resistant strains that skewed the latter value [28] Figure 2 . In vitro antimicrobial activity of meropenem against Pseudomonas aeruginosa selected for resistance to comparator antibiotics. White and black areas indicate, respectively, the proposed breakpoints for susceptibility (4 iig/mL) and moderate susceptibility (8 ktg/mL) to meropenem. Refer to figure 1 legend for MIC resistance breakpoints and drug abbreviations.
Drug (no. of strains) Figure 4 . In vitro antimicrobial activity of meropenem against gram-positive cocci selected for resistance to comparator antibiotics. White and black areas indicate, respectively, the proposed breakpoints for susceptibility (4 p,g/mL) and moderate susceptibility (8 pg/mL) to meropenem. Refer to figure 1 legend for MIC resistance breakpoints and drug abbreviations. . In vitro antimicrobial activity of meropenem against anaerobes selected for resistance to comparator antibiotics. White and black areas indicate, respectively, the proposed breakpoints for susceptibility (4 p,g/mL) and moderate susceptibility (8 pg/mL) to meropenem. Resistance breakpoints for other drugs were those recommended by the NCCLS: cefoxitin (Cfox), ._-64 pg/mL; metronidazole (Mtr), _-32 pg/mL; and clindamycin (Cm), ,--8 ktg/mL.
intentional inclusion of the resistant strains, the MIC 50 of meropenem (2 ,u,g/mL), rather than the corresponding MIC90 (8 ,ug/mL), may more accurately represent this compound's activity against randomly selected B. cepacia isolates. Meropenem's MIC90 against some fastidious isolates, such as H. influenzae (including ampicillin-resistant, 41-lactamaseproducing, or type b strains), was 64-fold greater than that of imipenem and generally comparable to the activities of the third-generation cephalosporins against these isolates, thus confirming the work of Powell et al. [29] . Likewise, meropenem was 8-fold more active than imipenem against N gonorrhoeae and N meningitidis, including /3-lactamase-producing strains of the former.
Carbapenems were also more active than cephalosporin or gentamicin against gram-positive bacteria, including S. pneumoniae and f3-lactamase-producing staphylococci. Meropenem and other comparators had low MIC50 values against the vast majority of gram-positive organisms. The MIC 90 values of all drugs against S. epidermidis were skewed because of the inclusion of an unknown number of methicillin-resistant strains. Although methicillin-resistant isolates are responsible for skewing the MIC90 values for these staphylococci, it is unlikely that /3-lactam drugs would be used clinically to treat infections caused by methicillin-resistant staphylococci.
Verma et al. [30] reported that methicillin-susceptible coagulase-negative staphylococci had low meropenem MIC 90 values. Carbapenems were frequently the most active agents against anaerobes, including B. fragilis and B. thetaiotaomicron, with an overall MIC90 of -.__2 btg/mL. The present report confirms the work of Nord et al. [3] , which demonstrates the excellent activity of meropenem against common anaerobic pathogens, including B. fragilis, B. thetaiotaomicron, and Clostridium species; meropenem was sometimes 2-to 4-fold more active than imipenem against such organisms.
When the antibacterial activity of meropenem against common pathogens at each center was compared, the percentages of resistant strains in each center were generally similar. In the four instances where the percentages of meropenem-resistant gram-negative rods were dissimilar to those tested in other centers, the tested organisms included large proportions of multidrug-resistant strains and were atypical of random populations. This was confirmed by the widespread enhanced degree of resistance exhibited to other broad-spectrum antimicrobials.
Meropenem, like most /3-lactam antibiotics, was bactericidal against Enterobacteriaceae organisms, gram-positive cocci, and P. aeruginosa, with low MBC/MIC ratios and MIC90 values in the clinically relevant range.
In summary, each of the 26 North American centers confirmed the excellent antimicrobial properties of meropenem against the, vast majority of potential pathogens, including those strains selected because of known resistance to one or more of the comparator drugs. The present study, in which raw data from each center were pooled for meta-analysis, supports and further extends the findings of the individual centers. Meropenem was more active than the comparators against most common randomly chosen or specifically selected antibioticresistant pathogens evaluated. Thus, these data suggest that meropenem may represent effective alternative empirical therapy for patients with moderate to severe monomicrobial or polymicrobial infections.
